These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25314930)

  • 1. [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
    Negri L; Le Grusse J; Séraissol P; Lavit M; Houin G; Gandia P
    Therapie; 2014; 69(6):509-16. PubMed ID: 25314930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic association between
    Khan S; Mandal RK; Elasbali AM; Dar SA; Jawed A; Wahid M; Mahto H; Lohani M; Mishra BN; Akhter N; Rabaan AA; Haque S
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30509962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.
    Ho HT; Wang TH; Hsiong CH; Perng WC; Wang NC; Huang TY; Jong YJ; Lu PL; Hu OY
    Pharmacogenet Genomics; 2013 Apr; 23(4):200-7. PubMed ID: 23407048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India.
    Shetty P; Panchal F; Munshi R; Sundar U; Darole P
    Indian J Tuberc; 2020 Jul; 67(3):407-410. PubMed ID: 32825881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
    Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
    Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
    Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
    Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
    Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
    Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
    Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
    In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation in the rat livers induced by low dosage isoniazid treatment.
    Zhang B; Sun S; Shen L; Zu X; Chen Y; Hao J; Huang X; Feng F
    Environ Toxicol Pharmacol; 2011 Nov; 32(3):486-90. PubMed ID: 22004970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The association between NAT2 polymorphism and anti-tuberculosis drug-induced hepatitis].
    Wu YM; Luo ZY; Zhang HM; Peng JF; Liu SY; Wang M
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):467-9. PubMed ID: 20587321
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
    Yamada S; Tang M; Richardson K; Halaschek-Wiener J; Chan M; Cook VJ; Fitzgerald JM; Elwood RK; Brooks-Wilson A; Marra F
    Pharmacogenomics; 2009 Sep; 10(9):1433-45. PubMed ID: 19761367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.
    Santos NP; Callegari-Jacques SM; Ribeiro Dos Santos AK; Silva CA; Vallinoto AC; Fernandes DC; de Carvalho DC; Santos SE; Hutz MH
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):499-504. PubMed ID: 23394127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
    Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
    Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.
    Ohno M; Yamaguchi I; Yamamoto I; Fukuda T; Yokota S; Maekura R; Ito M; Yamamoto Y; Ogura T; Maeda K; Komuta K; Igarashi T; Azuma J
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):256-61. PubMed ID: 10751073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.